419 related articles for article (PubMed ID: 28039080)
41. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
[TBL] [Abstract][Full Text] [Related]
42. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
43. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
[TBL] [Abstract][Full Text] [Related]
44. Mismatched related vs matched unrelated donors in TCRαβ/CD19-depleted HSCT for primary immunodeficiencies.
Laberko A; Sultanova E; Gutovskaya E; Shipitsina I; Shelikhova L; Kurnikova E; Muzalevskii Y; Kazachenok A; Pershin D; Voronin K; Shcherbina A; Maschan M; Maschan A; Balashov D
Blood; 2019 Nov; 134(20):1755-1763. PubMed ID: 31558465
[TBL] [Abstract][Full Text] [Related]
45. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
[TBL] [Abstract][Full Text] [Related]
46. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
[TBL] [Abstract][Full Text] [Related]
47. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
48. Lymphocyte subset at time of Epstein-Barr viremia post-allogeneic hematopoietic stem cell transplantation in children may predict development of post-transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor.
Althubaiti S; Ali S; Renzi S; Krueger J; Chiang KY; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Dec; 23(8):e13574. PubMed ID: 31496046
[TBL] [Abstract][Full Text] [Related]
49. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
[TBL] [Abstract][Full Text] [Related]
50. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
Zhou L; Gao ZY; Lu DP
Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
[TBL] [Abstract][Full Text] [Related]
51. [Prevalence of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
Han TT; Xu LP; Liu DH; Liu KY; Zhang XH; Chen H; Chen YH; Han W; Wang FR; Wang Y; Wang JZ; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):651-4. PubMed ID: 23978013
[TBL] [Abstract][Full Text] [Related]
52. Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease.
Xu LP; Zhang HY; Huang XJ; Liu KY; Liu DH; Han W; Chen H; Chen YH; Gao ZY; Zhang YC; Lu DP
Chin Med J (Engl); 2007 Oct; 120(19):1666-71. PubMed ID: 17935666
[TBL] [Abstract][Full Text] [Related]
53. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
[TBL] [Abstract][Full Text] [Related]
54. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.
Anderson-Smits C; Baker ER; Hirji I
Transpl Infect Dis; 2020 Dec; 22(6):e13396. PubMed ID: 32603496
[TBL] [Abstract][Full Text] [Related]
55. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
Ru Y; Chen J; Wu D
Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
[TBL] [Abstract][Full Text] [Related]
56. Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation.
Huang J; Pan Z; Wang L; Zhang Z; Huang J; Jiang C; Cai G; Yin T
Clin Exp Med; 2024 Jan; 24(1):22. PubMed ID: 38280072
[TBL] [Abstract][Full Text] [Related]
57. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation.
Li L; Chaudhuri A; Weintraub LA; Hsieh F; Shah S; Alexander S; Salvatierra O; Sarwal MM
Pediatr Transplant; 2007 Mar; 11(2):187-95. PubMed ID: 17300499
[TBL] [Abstract][Full Text] [Related]
58. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
59. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
60. Haploidentical Stem Cell Transplantation After TCR-αβ
Giardino S; Bagnasco F; Falco M; Miano M; Pierri F; Risso M; Terranova P; Di Martino D; Massaccesi E; Ricci M; Chianucci B; Dell'Orso G; Sabatini F; Podestà M; Lanino E; Faraci M
Transplant Cell Ther; 2022 Jul; 28(7):394.e1-394.e9. PubMed ID: 35405368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
